8-K filed Aug 5, 2026 at 07:04 ET
Entrada Therapeutics reported Q2 2026 results with collaboration revenue of $0.9M as the Vertex program winds down, and a GAAP net loss per share of -$1.01, beating the $-1.16 consensus by 12.9%. The company reiterated pipeline progress across its DMD franchise, with key data readouts for ELEVATE-45-201 Cohort 1 in October 2026 and ELEVATE-44-201 open-label data by year-end 2026. Cash of $223M provides runway into Q3 2027, but the significant year-over-year drop in collaboration revenue and ongoing operating losses keep the financial profile stable but unimproved.